Australia'snational member-based biotechnology organisation, AusBiotech, is delighted to announce the appointment of two new Non-Executive Directors to its Board of Directors; ProfessorJohn Skerritt, Enterprise Professor in Health Research Impact at theUniversity of Melbourneand DrLiz Dallimore, CEO and Managing Director,Argenica Therapeutics Ltd.

Seasoned health and life science leader ProfessorJohn Skerritthas been appointed to the AusBiotech Board, bringing decades of experience in research translation, commercialisation, policy and regulation.Professor Skerrittis the former Deputy Secretary of theAustralian Department of HealthandAged Care, and led theTherapeutic Goods Administration(TGA) for 10 years, he was also responsible for regulation of gene technology and industrial chemicals and control of drug import, export, and production.

Professor Skerritthas played a major role in advising the Australian Government on the establishment of an mRNA vaccines and medicines industry. He was previously the most senior scientific leader inAustralia'sForeign Affairs portfolio, leading implementation of more than$1billionin collaborative scientific programs betweenAustraliaand regional countries. He helped leadAustralia'sCOVID-19 response and was one of the public media faces of the response.

Professor Skerrittsaid, 'I am thrilled to have the opportunity to contribute to the success ofAustralia'slife sciences industry via the AusBiotech Board. I look forward to working with fellow Directors to advocate forAustralia'sbiotech industry and its tremendous potential inAustralia'shealth and economic wealth.'

DrJames Campbell, AusBiotech's Interim Chair, said that 'Professor Skerritt's appointment brings extensive government and policy experience as well as deep scientific experience to the Board. His connectivity with national initiatives and the broader sector will aid AusBiotech in working collaboratively to drive policy that reinforces the strength of biotechnology inAustralia'sfuture.'

DrLiz Dallimorehas also been appointed to the AusBiotech Board, and brings with her deep experience in both biotechnology and management consulting with more than 20 years' experience acrossAustraliaand theUK.

As the CEO and Managing Director ofArgenica Therapeutics(ASX:AGN), a West Australian clinical stage biotechnology company developing therapies to treat stroke and other neurological conditions,Dr Dallimoreled the company's ASX IPO inJune 2021and has advanced the company from pre-clinical research into a Phase 2 clinical trial in stroke patients. She is also the Co-Founder and Executive Chair of medical device companyInspiring Holdings, a company developing devices for improved inhaled drug delivery.

Dr Dallimorehas previously held senior roles in management consulting asKPMG'sNational Director of Research Engagement and Commercialisation, structuring technology commercialisation deals across a range of sectors. Prior to this, she held senior roles withErnst & YoungandPricewaterhouseCoopers.Dr Dallimoreis also a Non-Executive Director of theChamber of Commerce and Industry WA, and an industry advisor toTelethon Kids InstituteandCurtin University.

'I am honoured to be appointed to the AusBiotech Board of Directors, joining a group of dedicated and passionate industry leaders who are motivated to further grow and developAustralia'sworld-class life science ecosystem,'Dr Dallimoresaid.

On behalf of the AusBiotech Board,Dr Campbellstated his pleasure in welcoming bothProfessor SkerrittandDr Dallimoreto the Board as Non-Executive Directors. 'These new appointments bring fresh perspectives and insight that will position AusBiotech to represent the best interests of our diverse membership at the national level.'

In addition to the two new appointments, DrMegan Baldwin, Founder & Chief Innovation Officer,Opthea Ltd(ASX:OPT; NASDAQ:OPT), has been reappointed to the Board, formally commencing her third term as an appointed Non-Executive Director.

The new AusBiotech Board line-up includes: DrJames Campbell, CEO,Patrys Ltd; Interim Chair, AusBiotech

MsErica Kneipp, Research Director,Human Health,CSIRO; Deputy Chair, AusBiotech

DrMegan Baldwin, Chief Innovation Officer,Opthea Ltd(ASX:OPT); Risk and Audit Sub-Committee, Chair

DrDean Moss, CEO,UniQuest Pty Ltd; Remuneration and Nomination Sub-Committee, Chair

DrIris Depaz, Country Medical Lead & Head of Medical, Vaccines, Sanofi Australia &New Zealand

DrMarthe D'Ombrain, Head of Global Research Innovation,CSL Ltd

ProfessorJohn Skerritt, Enterprise Professor in Health Research Impact,University of Melbourne

DrLiz Dallimore, CEO & Managing Director,Argenica Therapeutics Ltd

MsLorraine Chiroiu, CEO & Managing Director, AusBiotech (until15 December 2023)

Contact:

Annabelle Dick

Email: [email protected]

Tel: +61 (0) 437 075 209

(C) 2023 Electronic News Publishing, sourceENP Newswire

https://www.marketscreener.com/quote/stock/ARGENICA-THERAPEUTICS-LIM-122796906/news/AusBiotech-energised-by-new-Board-appointments-45542468/